<?xml version="1.0" encoding="UTF-8"?><!-- generator="WordPress/2.6.5" -->
<rss version="0.92">
<channel>
	<title>htgenomics.com</title>
	<link>http://www.htgenomics.com</link>
	<description></description>
	<lastBuildDate>Thu, 02 Sep 2010 15:51:06 +0000</lastBuildDate>
	<docs>http://backend.userland.com/rss092</docs>
	<language>en</language>
	
	<item>
		<title>HTG Announces Appointments of John Wineman and Thomas Vasicek, Ph.D.</title>
		<description>HTG Announces Appointments of John Wineman as Vice President New Business Development--Western Region and Thomas Vasicek, Ph.D. as Vice President Clinical Programs and Product Innovation

TUCSON, Ariz., August 31, 2010 -- HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™),  today announced the appointments of John Wineman as Vice ...</description>
		<link>http://www.htgenomics.com/htg-announces-appointments-of-john-wineman-and-thomas-vasicek-phd-609.htm</link>
			</item>
	<item>
		<title>Luminex Corporation and HTG Launch qBead Assay</title>
		<description>LUMINEX CORPORATION AND HIGH THROUGHPUT GENOMICS
LAUNCH THE QBEAD ASSAY

LUMINEX TO DISTRIBUTE CO-DEVELOPED CUSTOM
GENE EXPRESSION PRODUCT

AUSTIN, Texas and TUCSON, Arizona – May 18, 2010 – Luminex Corporation (Nasdaq: LMNX), the worldwide leader in multiplexed solutions, and High Throughput Genomics, Inc. (HTG), provider of the quantitative Nuclease Protection Assay (qNPA™), today launched ...</description>
		<link>http://www.htgenomics.com/luminex-corporation-and-htg-launch-qbead-assay-590.htm</link>
			</item>
	<item>
		<title>HTG Signs Collaboration Agreement with John Wayne Cancer Institute</title>
		<description>HTG SIGNS COLLABORATION AGREEMENT WITH JOHN WAYNE CANCER INSTITUTE

Tucson, Ariz.—April 28, 2010—HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™), today announced it signed a collaboration agreement with the John Wayne Cancer Institute (JWCI) at Saint John's Health Center in Santa Monica, California. Under the terms of the agreement, ...</description>
		<link>http://www.htgenomics.com/htg-signs-collaboration-agreement-with-john-wayne-cancer-institute-592.htm</link>
			</item>
	<item>
		<title>HTG’s qNPA™ Technology selected for BARDA Grant</title>
		<description>ASU leads $40 million effort to rapidly assess radiation exposures
Dec. 21, 2009

TEMPE, Ariz.--Arizona State University will lead a $40.8 million, multi-institutional research program to develop systems that would rapidly measure an individual’s level of exposure to radiation in the event of a radiological or nuclear incident. In the event of ...</description>
		<link>http://www.htgenomics.com/htg%e2%80%99s-qnpa%e2%84%a2-technology-selected-for-barda-grant-544.htm</link>
			</item>
	<item>
		<title>Roche and High Throughput Genomics Partner for Advanced Gene Expression Analysis Solution</title>
		<description>Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) and High Throughput Genomics, Inc. (HTG), provider of the quantitative Nuclease Protection Assay (qNPA), have entered into a supply agreement. Under the agreement, Roche NimbleGen will provide HTG with high density, multiplex DNA microarray slides for advanced gene expression analysis. 

HTG will apply ...</description>
		<link>http://www.htgenomics.com/roche-and-high-throughput-genomics-partner-for-advanced-gene-expression-analysis-solution-535.htm</link>
			</item>
	<item>
		<title>HTG ANNOUNCES AVAILABILITY OF 96 MAX GENE EXPRESSION ASSAY</title>
		<description>HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™) today announced the launch of the quantitative Nuclease protection assay (qNPA™) 96 Max gene expression assay at the American Association of Cancer Research (AACR) annual meeting. This new testing configuration enables the measurement of 46 genes in a 96 well ...</description>
		<link>http://www.htgenomics.com/htg-announces-availability-of-96-max-gene-expression-assay-at-298.htm</link>
			</item>
	<item>
		<title>HTG and CRL Form Partnership</title>
		<description>HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™) and service partner for the life sciences industry, and Clinical Reference Laboratory, Inc. (CRL Global Services), provider of testing
services for toxicology, molecular diagnostics, clinical trials, bioanalytics, and insurance today
announced they signed a multi-year agreement. Under the terms of the agreement, ...</description>
		<link>http://www.htgenomics.com/htg-and-crl-form-partnership-250.htm</link>
			</item>
	<item>
		<title>HTG Collaborates with HC-LITT</title>
		<description>HTG SIGNS COLLABORATION AGREEMENT WITH HARVARD CATALYST LABORATORY FOR INNOVATIVE TRANSLATIONAL TECHNOLOGIES AT HARVARD MEDICAL SCHOOL

Tucson, Ariz.—December 1, 2008—HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™) system and service partner for the life sciences industry, today announced a collaboration agreement with researchers at Harvard Catalyst Laboratory for Innovative ...</description>
		<link>http://www.htgenomics.com/203-203.htm</link>
			</item>
	<item>
		<title>Fred Pollock Joins HTG</title>
		<description>HTG NAMES FREDRICK POLLOCK VP OF CORPORATE DEVELOPMENT

Tucson, Ariz.—November 24, 2008— HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™) system and service partner for the life sciences industry, today announced it has appointed Fredrick L. Pollock to Vice President of Corporate Development. Pollock will be responsible for leading ...</description>
		<link>http://www.htgenomics.com/fred-pollock-joins-htg-204.htm</link>
			</item>
	<item>
		<title>qNPA™ Technology Animation</title>
		<description>Click here to view a Technical Animation of the qNPA™ ArrayPlate. </description>
		<link>http://www.htgenomics.com/qnpaanimation-146.htm</link>
			</item>
</channel>
</rss>
